1911GCCC: Galeterone or Galeterone With Gemcitabine for Patients With Metastatic Pancreatic Adenocarcinoma

Clinical Trial ID NCT04098081

PubWeight™ 0.00^‹?›

🔗 Visit the ClinicalTrials.gov page for NCT04098081

Top papers

Rank	Title	Journal	Year	PubWeight™‹?›
1	New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).	Eur J Cancer	2009	77.71
2	FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.	N Engl J Med	2011	24.32
3	Optimal two-stage designs for phase II clinical trials.	Control Clin Trials	1989	21.03
4	Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.	N Engl J Med	2013	16.24
5	Role of NF-kappaB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death.	Oncogene	2003	2.96
6	Androgen Receptor Modulation Optimized for Response (ARMOR) Phase I and II Studies: Galeterone for the Treatment of Castration-Resistant Prostate Cancer.	Clin Cancer Res	2015	1.49
7	A phase II trial of nab-Paclitaxel as second-line therapy in patients with advanced pancreatic cancer.	Am J Clin Oncol	2013	1.30
8	Role of gemcitabine in cancer therapy.	Future Oncol	2005	1.29
9	Continuous toxicity monitoring in phase II trials in oncology.	Biometrics	2005	1.12
10	Gemcitabine triggers a pro-survival response in pancreatic cancer cells through activation of the MNK2/eIF4E pathway.	Oncogene	2012	1.05
11	Galeterone and VNPT55 disrupt Mnk-eIF4E to inhibit prostate cancer cell migration and invasion.	FEBS J	2016	0.75
12	Galeterone and its analogs inhibit Mnk-eIF4E axis, synergize with gemcitabine, impede pancreatic cancer cell migration, invasion and proliferation and inhibit tumor growth in mice.	Oncotarget	2016	0.75
13	Phase II study to evaluate combining gemcitabine with flutamide in advanced pancreatic cancer patients.	Br J Cancer	2002	0.75